SA EMS ROAD EXPERIENCE • HPCSA STATUTORY DRUG MONOGRAPH
ROCURONIUM BROMIDE
Rocuronium Bromide (Brand Names: Esmeron, Zemuron)
HPCSA CDST 2024 (Version 1.3 Framework)
Official Statutory Clinical Reference
Non-Depolarizing Neuromuscular Blocker • Aminosteroid Paralytic • RSI First-Line AgentHPCSA CDST 2024 (v1.3 Framework)
•
ROCURONIUM BROMIDE
Rocuronium Bromide (Brand Names: Esmeron, Zemuron)
Clinical Summary: An intermediate-acting non-depolarizing aminosteroid neuromuscular blocker that competitively antagonizes nicotinic acetylcholine receptors at the motor endplate, providing rapid, safe skeletal muscle flaccidity for emergency endotracheal intubation.
Authorized HPCSA Emergency Care Scope of Practice (Annexure A 2022)Statutory Board Mandate
ECP ONLY (~)
ROCURONIUM BROMIDE Audio BriefingCLINICAL PROFESSOR
No Audio Published Yet
00:00Full Monograph
1. Mechanism of Action
How this drug operates physiologically in the human body
2. Statutory Clinical Indications
2 UsesStrictly per HPCSA CDST v1.3, Annexure A & CPG
3. Adverse Effects & Pathophysiology
Why the body reacts and why it occurs in specific indications
4. Contraindications & Lethal Risks
Biological consequences & why it threatens life
5. Statutory Resources & Quotes
Verbatim regulatory excerpts with deep external links
SA EMS FIELD PROTOCOLS • EDUCATIONAL REVIEW & STATUTORY CITATIONS
An independent educational review and study companion based on the official HPCSA CDST 2024 (Version 1.3 Framework), CPG 2018, and Annexure A (2022) sourced directly from the official HPCSA publication portal. Not for live on-scene patient management.
Author: Jacoline (Jax) Geldenhuys, BEMC • HPCSA Registered Emergency Care Practitioner (ECP)